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Background: Remimazolam is an ultra-short acting benzodiazepine under development for 
procedural sedation and general anesthesia. It is hydrolyzed by CES1 to an inactive metabolite 
(CNS7054). 
Purpose: In this study, the effect of continuous remimazolam exposure on its metabolism and 
on CES1 expression was investigated in a dynamic 3-D bioreactor culture model inoculated 
with primary human hepatocytes.
Methods: Remimazolam was continuously infused into bioreactors for 5 days at a final con-
centration of 3,000 ng/ml (6.8 µM). In parallel, 2-D cultures were run with cells from the same 
donors, but with discontinuous exposure to remimazolam. 
Results: Daily measurement of clinical chemistry parameters (glucose, lactate, urea, ammo-
nia, and liver enzymes) in culture supernatants indicated no noxious effect of remimazolam 
on hepatocyte integrity as compared to untreated controls. Concentrations of remimazolam 
reached steady-state values of around 250 ng/ml within 8 hours in 3-D bioreactors whereas in 
2-D cultures remimazolam concentrations declined to almost zero within the same time frame. 
Levels of CNS7054 showed an inverse time-course reaching average values of 1,350 ng/ml in 
perfused 3-D bioreactors resp. 2,800 ng/ml in static 2-D cultures. Analysis of mRNA expression 
levels of CES1 indicated no changes in gene expression over the culture period. 
Conclusion: The results indicated a stable metabolism of remimazolam during 5 days of 
continuous exposure to clinically relevant concentrations of the drug. Moreover, there was no 
evidence for a harmful effect of remimazolam exposure on the integrity and metabolic activity 
of in vitro cultivated primary human hepatocytes.
Keywords: benzodiazepine, metabolite, CNS7054, carboxylesterase 1, steady state
Introduction
Remimazolam is a new ultrashort-acting benzodiazepine developed for use in sedation 
and anesthesia. Its sedative effect is caused by γ-aminobutyric acid–receptor modu-
lation, similarly to other sedatives. The drug contains a metabolically labile ester 
moiety and is rapidly hydrolyzed by tissue esterases.1 In the liver, hydrolysis is mainly 
catalyzed by CES12 resulting in an inactive carboxylic acid metabolite (CNS7054, 
Figure 1). This mechanism is responsible for the ultrashort action of the drug, similar 
to the tandem fentanyl–remifentanil. To date, four clinical trials for procedural seda-
tion have been published, showing a favorable safety profile for remimazolam with 
rapid sedation and recovery.3–6 However, exposure to remimazolam for .24 hours in 
an intensive care unit was associated with higher plasma concentrations than known 
from healthy volunteers, consistent with the possibility (reported for other drugs) 
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that prolonged exposure under traumatizing conditions may 
favor metabolic alterations.7 Since the liver is the main site 
of CES1 expression,2 alterations in hepatic functionality 
and CES1 expression might lead to drug accumulation after 
long-term exposure.
In order to test the long-term stability of human remima-
zolam metabolism and elucidate possible effects of prolonged 
drug application on hepatic functionality, we used an in vitro 
model of primary human liver cells cultured in a perfused 
3-D bioreactor system, which enables extended preservation 
of cell functionality. This bioreactor system consists of a 
capillary network enabling countercurrent medium perfu-
sion, decentralized oxygenation, and CO
2
 removal, while 
providing a scaffold for adherence and reorganization of 
inoculated liver cells similar to the in vivo environment.8 
The bioreactor was originally developed for extracorporeal 
liver support and successfully applied in a pilot study to 
support patients suffering from liver failure.9 In a further 
approach, the bioreactor was downscaled to analytical-scale 
variants to enable its application for pharmacological in vitro 
studies.10,11 The suitability of the bioreactor technology to 
assess human-liver drug metabolism and toxicity in vitro has 
been shown using different model drugs, such as paracetamol 
or diclofenac.12–14
In the present study, a dynamic 3-D bioreactor system 
containing primary human hepatocytes was used to investi-
gate the effects of continuous remimazolam application over 
5 days, thereby mimicking the situation of a patient receiving 
a continuous infusion of the drug. The effect of remimazolam 
on cell integrity and functionality in the 3-D bioreactor was 
assessed by daily measurement of clinical chemistry param-
eters (glucose, lactate, urea, ammonia, and liver enzymes). 
Possible alterations in remimazolam metabolism were evalu-
ated by analyzing the time course of remimazolam decrease 
and formation of its metabolite – CNS7054. In addition, 
mRNA expression of the CES1 gene, encoding CES1, the 
enzyme mainly involved in remimazolam metabolism, was 
determined at the end of remimazolam exposure. In paral-
lel, experiments in conventional collagen-coated 2-D plates 
were performed with cells from the same donors, but with 
discontinuous exposure to remimazolam. Therefore, direct 
comparison of remimazolam effects and metabolism in 
dynamic and static culture systems was possible.
Methods
human liver-cell isolation
The study was performed in three independent experiments 
with primary human hepatocytes from three different donors 
(Table 1). Cells were isolated from liver tissue resected due to 
tumor disease, with written informed consent by the patients. 
The study was conducted in accordance with the Declara-
tion of Helsinki and with approval of the ethics committee 
of the Charité – Universitätsmedizin Berlin (EA2/026/09, 
February 27, 2014). Cells were obtained by collagenase 
digestion from macroscopically healthy tissue as described 
elsewhere.15,16
Bioreactor
The 3-D hollow-fiber bioreactor system (Stem Cell Systems, 
Berlin, Germany) used in this study consists of three indepen-
dent but interwoven capillary bundles (Figure 2): two of them 
serve for countercurrent medium perfusion (media I and II) 










Donor 1 52 Male colorectal liver metastases
Donor 2 28 Female gastrointestinal stromal tumor 
metastases
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and the third for internal oxygenation (gas). Cells are cultured 
in the extracapillary space, which has a volume of 0.5 mL. 
They are allowed to adhere to the hollow-fiber scaffold and 
supplied with nutrients and oxygen through the capillary 
membranes (Figure 3A and C).
The capillary bed is incorporated into a polyurethane 
housing equipped with connectors for mounting the perfu-
sion tubing and for cell inoculation. The structure of the 
perfusion circuit is shown in Figure 4. Culture medium is 
constantly recirculated through the bioreactor by means of a 
peristaltic pump. At the same time, fresh culture medium is 
fed into the perfusion circuit via a second pump, while the 
corresponding excess medium is rinsed out into the waste 
vessel. A port integrated into the perfusion circuit enables 
substance injection and sampling from the recirculating 
medium. An electronic gas-mixing unit enables supply of 
air–CO
2
 at a defined mixture and flow rate.
3-D culture of hepatocytes in bioreactors
In order to minimize dilution of medium components and 
cell products in the perfusion circuit, the perfusion length and 
volume were kept as small as possible, while addressing tech-
nical requirements (pump segments, bubble trap), resulting 
in the experimental conditions summarized in Table 2. Flow 
rates of the recirculating medium were optimized to enable 
optimal mass exchange via diffusion through the capillary 
membranes. The medium-feed rate was set according to glu-
cose levels measured in the perfused medium to prevent glu-
cose starvation of the cultured cells. To allow the formation 
of parenchyma-like 3-D cell aggregates in spaces between the 
capillaries, inoculated cell numbers were determined based 
on the cell-compartment volume, approximating typical cell 
concentrations in the liver. Bioreactors were perfused with 
Figure 2 3-D bioreactor.
Note: The photograph shows the bioreactor with tube connectors for two medium 
capillary bundles, one gas capillary bundle, and cell inoculation, a tube connected to 






Figure 3 culture of primary human hepatocytes in 3-D bioreactors and 2-D cultures.
Notes: (A) Cell aggregates being cultured between the hollow-fiber capillaries of the bioreactor, providing the cells with gas and nutrients. (B) 2-D monolayer culture on 
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serum-free Heparmed culture medium (Biochrom, Berlin, 
Germany), a modification of the Williams Medium E devel-
oped for serum-free 3-D liver-cell culture. The medium was 
supplemented with ITG supplements (final concentrations: 
0.8 mg/L insulin, 5 mg/L transferrin, and 3 µg/L glucagon) 
and penicillin–streptomycin (100,000 U/L–100 mg/L), all 
purchased from Biochrom. The waste vessel was emptied 
daily, after taking samples for analysis.
2-D hepatocyte culture
In parallel to bioreactor cultures, experiments with cells from 
the same donor were performed in 2-D plates for comparison. 
Six-well culture plates (Falcon; BD Biosciences, San Jose, 
CA, USA) were coated with rat-tail collagen prepared accord-
ing to a protocol described previously.17 Freshly isolated 
human hepatocytes were suspended in Williams Medium E 
with GlutaMax (Thermo Fisher Scientific, Waltham, MA, 
USA), containing penicillin–streptomycin (100,000 U/L–
100 mg/L), 15 mM HEPES, 1 mM sodium pyruvate, 1% 
non essential amino acids, 10% FBS (all Thermo Fisher 
Scientific), 0.8 mg/L dexamethasone (Fortecortin; Merck, 
Darmstadt, Germany), and 1 mM human insulin (Sanofi 
Aventis, Frankfurt am Main, Germany), referred to as 
Figure 4 schematic illustration of the bioreactor perfusion circuit.
Notes: The tubing system contains two independent pumps for medium recirculation through the bioreactor and fresh medium feed, respectively, while rinsing out of 
used medium is driven by hydrostatic pressure increase (red, bioreactor-inflow tubing; blue, bioreactor-outflow tubing). The bioreactor disposes of two medium-perfusion 
capillary systems, which are countercurrently perfused to enhance mass exchange. each capillary layer consists of alternating medium and oxygen capillaries, with cells being 
cultured in the space between the capillaries. Cells are inoculated via a separate tube line. An electronically controlled gas-mixing unit provides defined flow rates of air and 
cO2 and allows for regulation of gas concentrations in the supplied gas mixture (gray lines). The temperature in the bioreactor chamber is constantly kept at 37°c via an 








Table 2 Bioreactor perfusion parameters and operation conditions
Parameters Set value during 
operation
Volume of bioreactor circuit 12 ml
Volume of cell compartment 0.5 ml
inoculated cell number 40×106
cell concentration in the cell compartment 80×106 cells/ml
recirculation rate 3 ml/min
Feed rate 0.5 ml/h
Gas-flow rate 5 ml/min




Temperature in bioreactor chamber 37°c
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“full medium”. Cells were seeded in the collagen-coated 
plates at a density of 1.4 million cells per well (Figure 3B 
and D). From 24 hours onward, the culture medium was 
exchanged daily with the same medium, but without FBS 
and hormones (starving medium).
Preparation of remimazolam solution
Remimazolam (PAION UK Ltd, Cambridge, UK) was dis-
solved in water for injection at a concentration of 2.5 mg/
mL, followed by dilution in 0.9% NaCl solution, resulting in 
a substance concentration of 100 µg/mL. This solution was 
further diluted in culture medium to the desired concentra-
tion prior to use.
remimazolam application in 3-D 
bioreactors
In a preliminary study, the adsorption behavior of remima-
zolam was investigated in a cell-free bioreactor. Remimazolam 
was applied at a final concentration of 500 ng/mL (1.1 µM) 
into the bioreactor circuit, and perfusion with the substance 
was performed over 24 hours in a closed circuit. Remimazolam 
concentrations, analyzed at 0 hours (after starting closed 
recirculation), 1 hour, 2 hours, 4 hours, 8 hours, and 24 hours, 
revealed a substance loss of nearly 85% in the system (data 
available online at http://doi.org/10.5281/zenodo.1493510, 
file Adsorption_study). Based on these results, the con-
centration of remimazolam in the bioreactor perfusate was 
increased to 3,000 ng/mL (6.8 µM) in the main study, which 
resulted in a concentration of around 850 ng/mL in cell-free 
bioreactors (data available online at http://doi.org/10.5281/
zenodo.1240206, file Remimazolam_3D_bioreactors), which 
is in the range of clinically observed plasma concentrations.
The experimental design of the main study is depicted 
in Figure 5. Subsequently to cell inoculation, cultures were 
maintained for 3 days without drug application to allow the 
cells to recover from cell isolation and adapt to the system. 
The application of remimazolam was initiated on day 3 and 
continued until day 8 of bioreactor culture. To achieve an 
immediate final concentration of 3,000 ng/mL (6.8 µM) in 
the perfusion circuit, 1 mL culture medium containing the 
12-fold concentration of remimazolam was injected into 
the recirculating medium, simulating a bolus application in 
the clinical setting. Subsequently, perfusion was performed 
with constant feed of remimazolam at a concentration of 
3,000 ng/mL (6.8 µM) into the circuit, thereby mimicking 
an infusion regime following a bolus.
In each experiment, a further bioreactor run in parallel 
without hepatocytes was exposed to remimazolam to enable 
point-to-point corrections for nonmetabolic loss of remima-
zolam in the device. A third bioreactor was inoculated with 
hepatocytes, but not treated with remimazolam to provide 
a negative control for evaluation of possible remimazolam 
effects on the cultured primary human hepatocytes.
remimazolam exposure in 2-D cultures
In parallel with 3-D cultures, 2-D hepatocyte cultures 
were incubated from day 3 to day 8 of culture with 
starving medium containing remimazolam at a final con-
centration of 3,000 ng/mL (6.8 µM). Parallel cultures 
were maintained without remimazolam exposure as a 
negative control. The culture medium was exchanged 
daily after taking samples for analysis. Since preliminary 
studies performed in cell-free culture plates revealed no 
relevant substance loss in 2-D systems (data available 
&HOOLQRFXODWLRQ &XOWXUHWHUPLQDWLRQ
G G G G G G G G G'DLO\PHDVXUHPHQWRIPHWDEROLFSDUDPHWHUVJOXFRVHODFWDWHXUHDDPPRQLD/'+$67$/7*/'+ P51$DQDO\VLVRI&(6
0HDVXUHPHQWRIUHPLPD]RODP&16K K K KK 5HPLPD]RODPDSSOLFDWLRQ&XOWXUHDGDSWDWLRQ K
Figure 5 experimental design of the study. 
Notes: After cell inoculation, bioreactors were first perfused with drug-free medium over 3 days for culture adaptation. From day 3 on ward, remimazolam was applied 
continuously until day 8 of culture. Two further bioreactors were run in parallel in each experiment: one without cells, which was perfused with remimazolam to assess 
possible substance loss in the system, and one with cells, but perfused without remimazolam as a negative control for detection of potential effects on cell metabolism.
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online at http://doi.org/10.5281/zenodo.1493510, file 
Adsorption_study), cell-free controls were not included in 
2-D experiments.
analysis of clinical chemistry parameters
Parameters reflecting the cell integrity and metabolic activity 
were measured on a daily basis in the recirculating medium 
of 3-D hepatocyte bioreactors and in supernatants of paral-
lel 2-D cultures. Concentrations of lactate dehydrogenase 
(LDH), alanine aminotransferase (ALT), aspartate transami-
nase (AST), glutamate dehydrogenase (GLDH), ammonia, 
and urea were determined at Labor Berlin, Berlin, Germany 
using clinical analyzers. Glucose and lactate concentrations 
were measured with a blood-gas analyzer (Radiometer, 
Copenhagen, Denmark).
analysis of remimazolam metabolism
Samples for analysis of remimazolam and its main metabo-
lite, CNS7054, were collected from the recirculating medium 
and waste vessels of bioreactors at 0 hours (after starting the 
substance application), 1 hour, 2 hours, 4 hours, 8 hours, 
and 24 hours, and thereafter daily at 48 hours, 72 hours, 
96 hours, and 120 hours. Samples from supernatants of par-
allel 2-D cultures were taken at the same time points, using 
individual wells for each time point of analysis. Concentra-
tions of remimazolam and CNS7054 were analyzed at Aptuit 
(Verona, Italy) using a validated method. Compounds were 
extracted by protein precipitation and analysis performed 
by using HPLC with tandem mass spectrometry detection 
as previously described.3
analysis of CES1 gene expression
Cell samples for gene-expression analysis of CES1 were 
collected from 3-D bioreactors exposed or not exposed to 
remimazolam upon culture termination on day 8. Samples 
from parallel 2-D cultures were taken at 0 hours (after start-
ing the experiment), 24 hours, 72 hours, and 120 hours using 
individual wells for each time point of analysis. RNA was 
extracted using Trizol reagent (Thermo Fisher Scientific) 
according to the manufacturer’s instructions. Afterward, 
genomic DNA was digested with an RNase-free DNase set 
(Qiagen, Venlo, the Netherlands). RNA concentrations were 
measured using spectrometry (Thermo Fisher Scientific), 
and 1 µg RNA served as a template to synthesize cDNA 
with a high-capacity cDNA reverse-transcription kit with 
RNase inhibitor (Thermo Fisher Scientific). Each cDNA 
template was mixed with PCR Master Mix (Thermo Fisher 
Scientific) and human-specific primers and probes for CES1 
(Hs00275607_m1, TaqMan gene-expression assay system; 
Thermo Fisher Scientific). Quantitative real-time PCR 
was performed using a real-time cycler (Mastercycler Ep 
Realplex 2; Eppendorf, Hamburg, Germany). Expression 
of CES1 was normalized to expression values of the house-
keeping gene GAPDH (Hs03929097_g1) and fold changes 
of expression levels calculated with the ΔΔCt method.18
Data calculation and evaluation
Data were evaluated using GraphPad Prism 5.0 (GraphPad 
Software, San Diego, CA, USA). Experiments were per-
formed with cells of three different donors, and results 
are presented as means ± SD. Total rates of remimazolam 
decrease and CNS7054 formation rates in bioreactors were 
calculated using Equation 1, where C
R
(t) is concentration in 
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. Net decrease/formation rates 
were calculated by subtracting values of cell-free bioreactors 
from those in cell-containing bioreactors using Equation 2.
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Influence of remimazolam on cell integrity 
and functionality
In order to evaluate a possible effect of remimazolam on 
the integrity and metabolic activity of primary human hepa-
tocytes in the 3-D bioreactors or 2-D cultures, glucose and 
nitrogen metabolism and enzyme release were determined 
in daily samples from cultures with or without remimazolam 
application.
In general, the time courses of clinical chemistry parameters 
were similar in cultures exposed or not exposed to remimazolam, 
indicating the absence of noxious effects of remimazolam and 
its metabolites on hepatocyte integrity and functionality during 
the course of the experiment (Figures 6 and 7). 
Glucose and lactate production, investigated as param-
eters for energy metabolism, showed slight differences in 
time courses between 3-D and 2-D cultures. In bioreactor 
cultures, initial net glucose release during the first days of 
culture was followed by net equilibrium between glucose 
influx and efflux from day 4 onward (Figure 6A). In contrast, 
2-D cultures showed a net uptake of glucose on the first day, 
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from day 2 onward or returning to a net uptake of glucose 
from day 4 onward for 2-D cultures with remimazolam 
application (Figure 6B). Lactate production showed a similar 
time course in 3-D and 2-D cultures, with decreasing values 
during the first days of culture and a subsequent increase 
reaching a maximum on day 7 (3-D) or day 4 (2-D) of culture 
(Figure 6C and D). Urea synthesis to assess cell capacity for 
nitrogen elimination was higher in 3-D than in 2-D cultures. 
After an initial peak, urea-secretion rates declined in both 
culture systems until day 2 (2-D) or day 4 (3-D), followed 
by a stable phase in 3-D cultures, whereas 2-D cultures 
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Figure 6 glucose and nitrogen metabolism in primary human hepatocytes.
Notes: cells were cultured in perfused 3-D bioreactors (left column) or static 2-D cultures (right column) without (black circles) or with remimazolam (rem) application 
(blue squares). (A, B) glucose production; (C, D) lactate production; (E, F) urea production; (G, H) ammonia release; n=3, means ± sD. Underlying data can be found online 
at http://doi.org/10.5281/zenodo.1493510 (files Clinical_chemistry_3D_bioreactors and Clinical_chemistry_2D_cultures).
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Ammonia release was investigated as a further parameter 
for nitrogen metabolism, and showed a similar time course 
as urea production rates in 3-D bioreactors, characterized by 
an initial peak followed by stable values from day 3 onward 
(Figure 6G). In contrast, ammonia release in 2-D cultures 
showed a distinct increase over time (Figure 6H). 
Release rates of LDH (Figure 7A and B) and the liver 
enzymes ALT, GLDH, and AST (Figure 7C–H) showed a 
steady decline during the first days of culture and remained on 
basal levels afterward in both culture systems, providing no 
indication of cell injury caused by remimazolam application.
Time-dependent metabolism of 
remimazolam
Time courses of remimazolam decrease and formation of its 
main metabolite CNS7054 were studied in primary human 
hepatocytes cultured in 3-D bioreactors or 2-D cultures 
during an exposure period of 5 days (120 hours). Investiga-
tion of remimazolam concentrations in recirculating media 
of bioreactor cultures showed a decrease from an initial 
2,947±320 ng/mL, which corresponds to the applied final con-
centration, to steady-state values in the range of 250 ng/mL 
(Figure 8A). The steady state was reached after 4 hours and 
maintained until the end of the experiment. Concentrations 
of remimazolam’s main metabolite CNS7054 showed an 
inverse course, with a strong increase within 4 hours after 
remimazolam application in the recirculating medium 
(Figure 8A). A stable level at an average of 1,350 ng/mL was 
attained after ~24 hours and maintained throughout the test 
period. Measurements performed in 2-D cultures during the 
first 24 hours showed that concentrations of remimazolam in 
culture supernatants decreased rapidly from an initial value 
Figure 7 enzyme release of primary human hepatocytes.
Notes: cells were cultured in perfused 3-D bioreactors (left column) or in static 2-D cultures (right column) without (black circles) or with remimazolam (rem) application 
(blue squares). (A, B) lDh release; (C, D) alT release; (E, F) asT release (G, H) glDh release; n=3, means ± sD. Underlying data can be found online at http://doi.
org/10.5281/zenodo.1493510 (files Clinical_chemistry_3D_bioreactors and Clinical_chemistry_2D_cultures).
Abbreviations: alT, alanine aminotransferase; asT, aspartate transaminase; glDh, glutamate dehydrogenase; lDh, lactate dehydrogenase.
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of 2,274±83 ng/mL to 68±46 ng/mL within 4 hours and to 
nearly zero within 24 hours after drug application (Figure 8B). 
Measured concentrations of CNS7054 presented an inverse 
curve, showing an increase from zero to 2,412±551 ng/mL 
2 hours after remimazolam application, followed by a slower 
increase to a maximum concentration of 2,763±618 ng/mL 
after 24 hours (Figure 8B). Concentrations of remimazolam 
and CNS7054 determined at 48 hours, 72 hours, 96 hours, 
and 120 hours were similar to those detected at 24 hours.
Based on concentrations measured in 3-D bioreactors, 
total decrease rates of remimazolam and corresponding 
total formation rates of CNS7054 were calculated and 
corrected with respect to concentration changes observed 
in cell-free bioreactors to obtain cell-specific net decrease 
rates and net formation rates (Figure 8C). Net rates of 
remimazolam decrease and CNS7054 formation showed 
maximum values 1–2 hours after substance application, with 
net rates amounting to 8,736+3,494 ng/h for remimazolam 
and to 3,512+1,401 ng/h for CNS7054 (Figure 8C). After-
ward, values decreased until 24 hours after remimazolam 
application, followed by a continuous metabolic decrease of 
remimazolam at an average net rate of ~250 ng/h. The con-
current formation of CNS7054 amounted to an average net 
rate of ~600 ng/h, and hence calculated net formation rates 
of CNS7054 exceeded net decrease rates of remimazolam.
In 2-D cultures, decrease rates of remimazolam and 
formation rates of CNS7054 calculated from concentration 
profiles reached maximum values during the first hour of 
incubation, amounting to 2,821±454 ng/h for remimazolam 
decrease and 3,088±927 ng/h for CNS7054 formation rate 
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Figure 8 remimazolam metabolism in primary human hepatocytes.
Notes: concentrations of remimazolam and cns7054 in (A) 3-D bioreactor circuit or (B) 2-D culture supernatants. Decrease rates of remimazolam and corresponding 
formation rates of cns7054 in (C) 3-D bioreactors or (D) 2-D cultures; n=3, means ± sD. Underlying data can be found online at http://doi.org/10.5281/zenodo.1493510 
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(Figure 8D). Both rates declined to almost zero within 
8 hours. From 24 hours on ward, calculated average drug 
decrease and product formation rates were maintained at 
stable values amounting to ~190 ng/h for remimazolam and 
to ~240 ng/h for CNS7054, indicating a slight imbalance 
toward product formation (Figure 8D). On the basis of the 
concentration profile determined for the first 24 hours over 
several time points, concentration profiles were modeled 
for the following 96 hours, assuming an identical time 
course as on the first day, to display the actual time course 
in discontinuous 2-D cultures (Figure 9). Here, it became 
apparent that cells in 2-D cultures were exposed to remima-
zolam for only the first few hours after medium exchange 
(Figure 9A) until the drug had completely converted to 
CNS7054 (Figure 9B). Therefore, in 2-D cultures, cells 
were exposed to strongly fluctuating concentrations of the 
drug and its metabolite, which is in contrast to the dynamic 
3-D bioreactors, where a steady state was reached through 
constant infusion of the parent drug.
Neither culture system showed a manifest decline in 
remimazolam decrease or product formation during the 
incubation period of 5 days.
gene expression of CES1
mRNA expression of CES1 was analyzed in 3-D bioreac-
tors after 120 hours (Figure 10A), and in 2-D cultures after 
24 hours, 72 hours, and 120 hours of remimazolam incubation 
(Figure 10B). Relative expression levels of CES1 in drug-
treated cultures were marginally increased (1.3–1.5-fold) 

















Figure 9 Modeled time courses of remimazolam metabolism in 2-D cultures.
Notes: Measured concentrations (solid lines) of (A) remimazolam and (B) cns7054 in 2-D cultures with primary human hepatocytes and time courses modeled on the basis 
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the data indicated no significant effect of remimazolam on 
the expression level of CES1.
Discussion
In this study, the metabolism of remimazolam to its main 
metabolite CNS7054 and possible effects of remimazolam 
exposure on the cell integrity and metabolic activity of pri-
mary human hepatocytes were investigated. The cells were 
cultured in a dynamic bioreactor system, which enabled 
continuous application of remimazolam, simulating clini-
cal drug administration via infusion. Parallel experiments 
were performed in static 2-D cultures with discontinuous 
drug application.
In accordance with previous observations,12–14 concentra-
tions of metabolic parameters, including glucose, lactate, 
urea, and liver enzymes, showed increased values in both 
culture systems during the first few days of culture, ie, prior 
to drug application. It has been shown that the isolation 
process leads to oxidative stress in primary hepatocytes.19 
Therefore, the finding of enhanced metabolite release could 
have been due to cell stress resulting from liver digestion. 
Parameters reached a stable level after a few days, indicat-
ing cell recovery and adaptation to the system. In the fol-
lowing experimental period, characterized by remimazolam 
application beginning on day 3 for a period of 5 days, stable 
maintenance of most metabolic parameters was observed 
in both 3-D bioreactors and 2-D cultures. Notably, the 
observed increase of ammonia release in 2-D cultures 
indicated a decrease in nitrogen elimination, which was 
not detected in 3-D cultures. Neither metabolic markers 
nor enzyme release pointed to possible noxious effects of 
remimazolam or its main metabolite CNS7054 during the 
course of experiments. Studies have shown that the applied 
3-D culture model is able to detect toxic effects in primary 
human hepatocytes applying the known hepatotoxic drugs 
diclofenac or paracetamol.12,13 In both studies, lactate and 
ammonia release rates were significantly affected in 3-D 
bioreactor cultures treated with increased drug concentrations 
compared to untreated control cultures.
The results from measuring remimazolam decrease 
and CNS7054 formation indicated stable remimazolam 
metabolism in the bioreactor system, with no manifest decline 
during the observed culture period of 5 days. The finding of 
a peak in net drug decrease and product formation during 
the first few hours of exposure can be attributed to increased 
concentrations of remimazolam immediately after drug 
application, which would correspond to a bolus injection in 
patients. After 8 (remimazolam) and 24 hours (CNS7054), 
steady states were reached in the bioreactor system and 
maintained over the following culture period of 5 days. 
A similar time course for remimazolam metabolism was 
observed in 2-D cultures. However, it has to be taken into 
account that the remimazolam application was discontinu-
ous in 2-D cultures, ie, fresh medium was only provided 
every 24 hours. Therefore, daily values reflected the aver-















Figure 10 CES1 expression in primary human hepatocytes.
Notes: cells were cultured in 3-D bioreactors or 2-D cultures for up to 120 hours after starting remimazolam application. (A) cells cultured in 3-D bioreactors were 
harvested after 120 hours for mrna expression analysis. (B) samples from 2-D cultures were taken after 24 hours, 72 hours, and 120 hours from individual wells. expression 
of CES1 was normalized to that of the housekeeping gene GAPDH, and fold changes in expression levels of remimazolam-treated cultures compared to untreated control 
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the actual time course between each medium exchange was 
characterized by an exponential decrease, similarly to that of 
the first day of culture. This leads to the conclusion that in 
the present study, the main advantage of the 3-D bioreactor 
model appears to be the perfusion condition and not the cul-
tivation in a 3-D environment. Subsequent studies should be 
designed to separate the effects of perfusion and cultivation to 
allow detailed conclusions regarding the effect of the culture 
environment on drug metabolism in human hepatocytes.
Several studies have shown dedifferentiation pro-
cesses in 2-D cultures, including lower drug-metabolizing 
activities,11,20,21 that can be attributed to the lack of physi-
ological cell reorganization and cell–cell contacts.22 A 
previous study examining the CYP-dependent metabolism 
of standard compounds, such as diclofenac and midazolam, 
showed distinct differences between 2-D and 3-D cultured 
primary human hepatocytes.11 The metabolic pattern of 
diclofenac and formation rates of corresponding metabolites 
exponentially decreased in 2-D cultures over 6 days, whereas 
stable conversion rates were maintained in perfused 3-D bio-
reactors.11 As such, the finding that CES1 activity remained 
unchanged in 2-D cultures over the investigated time period 
indicated that CES1 was less affected by dedifferentiation 
processes than other enzyme systems, such as CYP enzymes.
A correction of values was required in 3-D bioreactors, 
considering the nonmetabolic disappearance of remima-
zolam, which can be explained by substance adsorption 
in plastic tubing used for bioreactor perfusion, which is a 
well-known phenomenon in dynamic in vitro systems.23–25 
The investigation of remimazolam decrease in cell-free 
bioreactors indicated a remarkable loss of the substance, 
which can be ascribed to adsorption processes. The calcula-
tion of net decrease rates was based on subtracting the rates 
measured in cell-free bioreactors from those measured in 
cellularized bioreactors. The observation that the net rate of 
CNS7054 formation exceeded the net rate of remimazolam 
decrease in hepatocyte bioreactors may be explained by a 
lower adsorption of remimazolam to bioreactor materials 
in the presence of cells. In 2-D culture systems, which 
showed no substantial drug loss under cell-free conditions, 
remimazolam decrease and CNS7054 formation rates were 
almost identical, which further confirms the hypothesis of 
an overestimation of adsorption rates when calculating net 
rates in 3-D bioreactors.
However, the finding of stable remimazolam metabo-
lism was not affected by possible overcorrection, since the 
bioreactor cultures showed fairly constant levels of the free 
drug and its main metabolite from about 8 hours onward, 
CNS7054 reaching its steady state somewhat later compared 
to remimazolam. In addition, steady-state concentrations of 
remimazolam measured in this study (250 ng/mL) were in 
the range of venous plasma concentrations obtained during 
a phase I clinical study, where maximum remimazolam con-
centrations of 190–6,100 ng/mL (corresponding to unbound 
drug concentrations of 15–720 ng/mL with human protein 
binding of 92%) were observed depending on the applied 
drug dose.3 Moreover, there was no difference in CES1 
expression between drug-treated and untreated cultures, 
which further confirms stable preservation of remimazolam 
metabolism over the experimental period. To validate this 
observation further, CES1 expression should be analyzed at 
the protein level in future studies. The influence of remima-
zolam and its metabolite on CYP gene and protein expres-
sion was not investigated in this study, since results from 
metabolite analysis in plasma and urine samples from patients 
indicate that CYP enzymes do not substantially contribute 
to remimazolam metabolism.26
In contrast to the 3-D bioreactor cultures, which allow 
continuous drug infusion and thus maintenance of a constant 
drug concentration, the available drug concentration in 2-D 
cultures is strongly fluctuating, since the parent drug is 
quickly hydrolyzed and the metabolite accumulates under the 
conditions of discontinuous medium exchange. Therefore, 
the dynamic 3-D bioreactor more closely reflects the situation 
of a patient receiving a constant infusion of remimazolam 
during induction and maintenance of general anesthesia. 
On the other hand, 2-D cultures have the advantage that 
cell samples can be taken on a daily basis to investigate the 
time course of gene expression and/or other investigations, 
eg, protein determination. In the applied bioreactor system, 
regular cell-sample taking would destroy reorganized 3-D 
cell aggregates, and for this reason cell analyses were per-
formed only at the end of the experiment. In addition, the 
experimental design needs to consider possible substance 
adsorption to plastic tubing used for bioreactor perfusion. 
As such, both culture systems have valid reasons for being 
applied in in vitro pharmacological studies.
Conclusion
Exposure to remimazolam over 5 days at clinically relevant 
concentrations did not significantly influence remimazolam 
metabolism in the present in vitro study. The gene expression 
of CES1, the enzyme responsible for metabolic inactivation 
of remimazolam, was not affected either. Moreover, there 
was no indication of a harmful effect of remimazolam expo-
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As such, the results of the present study provide no 
indication that the phenomenon of high plasma concentra-
tions observed in patients during long-term treatment with 
remimazolam in the intensive care unit is related to a direct 
(auto)inhibitive effect of the parent drug or its metabolite(s) 
on function and expression of CES1. However, it has to be 
considered that systemic factors, which cannot be detected 
in the in vitro liver model used, may influence remima-
zolam metabolism during long-term exposure in severely 
ill patients. In addition, longer study periods would be of 
interest for future studies to exclude a functional decrease 
occurring after .120 hours. Such studies may be increasingly 
needed, as the number of drugs undergoing CES-mediated 
hydrolysis is steadily growing.27,28
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